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Aim: Risperidone is the most commonly prescribed antipsychotic drug to children
and adolescents worldwide, but it is associated with serious side effects, including
weight gain. This study assessed the relationship of risperidone and
9-hydroxyrisperidone trough concentrations, maximum concentrations and 24-hour
area under the curves (AUCs) with body mass index (BMI) z-scores in children and
adolescents with autism spectrum disorder (ASD) and behavioural problems. Second-
ary outcomes were metabolic, endocrine, extrapyramidal and cardiac side effects and
effectiveness.
Methods: Forty-two children and adolescents (32 males) aged 6-18 years were
included in a 24-week prospective observational trial. Drug plasma concentrations,
side effects and effectiveness were measured at several time points during follow-
up. Relevant pharmacokinetic covariates, including medication adherence and
CYP2D6, CYP3A4, CYP3A5 and P-glycoprotein (ABCB1) genotypes, were measured.
Nonlinear mixed-effects modelling (NONMEM®) was used for a population pharma-
cokinetic analysis with 205 risperidone and 205 9-hydroxyrisperidone concentra-
tions. Subsequently, model-based trough concentrations, maximum concentrations
and 24-hour AUCs were analysed to predict outcomes using generalized and linear
mixed-effects models.
Results: A risperidone two-compartment model combined with a
9-hydroxyrisperidone one-compartment model best described the measured concen-
trations. Of all the pharmacokinetic parameters, higher risperidone sum trough con-
centrations best predicted higher BMI z-scores during follow-up (P < .001). Higher
sum trough concentrations also predicted more sedation (P < .05), higher prolactin
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levels (P < .001) and more effectiveness measured with Aberrant Behavior Checklist
irritability score (P < .01).
Conclusion: Our results indicate a therapeutic window exists, which suggests that
therapeutic drug monitoring of risperidone might increase safety and effectiveness in
children and adolescents with ASD and behavioural problems.
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1 | INTRODUCTION
Risperidone is the most frequently prescribed antipsychotic drug to
children and adolescents worldwide, with a prevalence ranging from
1.1 to 6.6 per 1000 youths across different countries.1,2 In this popu-
lation risperidone is used for a broad range of mental health disorders,
including disruptive behavioural disorders, schizophrenia and bipolar
disorder. An important and increasing indication concerns irritability
associated with autism spectrum disorder (ASD), with almost one in
nine youths with ASD using risperidone.3 For these and other indica-
tions, the short-term efficacy of risperidone is well established and
supported by numerous randomized controlled trials.4,5
However, there are growing concerns about the side effects of
risperidone in children and adolescents. Weight gain is the most
important adverse effect, which is more pronounced in youths than in
adults.6 Children and adolescents gain several kilograms during the
first weeks of risperidone treatment.7 This results in serious long-term
health risks, including metabolic abnormalities and diabetes
mellitus.8,9
Other common side effects of risperidone include extrapyramidal
symptoms (EPS), prolactin elevation and sedation.10 During long-term
risperidone treatment, up to one in three youths experience mild to
moderate EPS, and more than half demonstrate prolactin elevations,
possibly leading to gynecomastia, galactorrhea and sexual dysfunc-
tion.11,12 Risperidone-induced sedation is significantly more prevalent
in young patients than in adults.13 Lastly, risperidone can increase the
corrected QT (QTc) interval, although clinically relevant QTc prolonga-
tion is rare.14
Several studies have shown that the risk of most of these side
effects, including weight gain, increases with higher risperidone dos-
ages in children and adolescents.9,11,15,16 However, the relationship
between individual exposure, reflected in risperidone plasma concen-
trations, and side effects remains unclear. A few studies have shown a
correlation between prolactin elevation and plasma concentrations of
risperidone or its active metabolite 9-hydroxyrisperidone in
youths,16–20 but the relationship with weight gain and other side
effects is unknown. This hampers the use of therapeutic drug moni-
toring to improve safety in this population.
The concentration-effectiveness relationship of risperidone in
children and adolescents has yet to be determined. One study
showed no correlation between total plasma risperidone and
9-hydroxyrisperidone concentrations and clinical response in a pro-
spective cohort of children with ASD.21 However, in that study,
both trough and nontrough risperidone concentrations were
analysed together, which prevents correct interpretation. Another
study found a concentration-effectiveness relationship in a sample
of children and adolescents with different indications for risperi-
done use, but this study had limitations due to the naturalistic and
retrospective study design.22
What is already known about this subject
• Risperidone treatment in children and adolescents is
associated with serious side effects, most importantly
weight gain.
• The risk of side effects increases with higher dosages, but
the relationship of concentrations of risperidone and its
active metabolite 9-hydroxyrisperidone with side effects
is unknown.
What this study adds
• In children and adolescents with autism spectrum disor-
der (ASD), weight gain can be predicted by model-based
risperidone sum trough concentrations. The sum trough
concentration is a better predictor than the maximum
concentration or the 24-hour area under the curves.
• Higher risperidone sum trough concentrations predict
higher body mass index z-scores, but also more sedation,
higher prolactin levels and, interestingly, more
effectiveness.
• Our findings indicate that a therapeutic window for
effectiveness with acceptable weight gain in children and
adolescents with ASD seems to exist, but more research
is needed to establish the therapeutic reference range in
this vulnerable population.
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Here we study for the first time the relationship between risperi-
done and 9-hydroxyrisperidone plasma concentrations, weight gain,
other side effects and effectiveness in a prospective cohort of chil-
dren and adolescents with ASD. The primary aim is to investigate the
relationship between model-based individual pharmacokinetic param-
eters and body mass index (BMI) z-scores. For this purpose, trough
concentrations, maximum concentrations and 24-hour area under the
curves (AUCs) are analysed. The relationships between the most rele-
vant pharmacokinetic parameter and EPS, sedation, metabolic abnor-
malities, prolactin elevation, QTc-prolongation and effectiveness are
also investigated. The influence of a large number of demographic and
biochemical characteristics, including the cytochrome P450 enzymes
CYP2D6, CYP3A4, CYP3A5 and P-glycoprotein (ABCB1) genotypes, is
taken into account.
The findings of this study should indicate whether there is a
therapeutic window and rationale for therapeutic drug monitoring
of risperidone to improve the safety and effectiveness in children
and adolescents.
2 | METHODS
2.1 | Study population
Children aged 6-18 years with the diagnosis of ASD according to the
Diagnostic and Statistical Manual of Mental Disorders (DSM) IV23 or
524 and using or starting risperidone for irritability were eligible for
inclusion in this 24-week observational prospective multicenter
cohort study (Netherlands Trial Register 6050). Exclusion criteria were
diabetes type I or II, congenital or acquired syndromes associated with
changes in appetite, body weight or lipid profile (eg, Prader Willi),
treatment with another antipsychotic drug within the last 6 months or
known long QT syndrome. Patients were treated in one of the seven
participating centres in the south-west region of the Netherlands (two
academic tertiary care centres and five psychiatric secondary care
centres). They were prescribed risperidone as tablet formulation or
oral solution in flexible dosing schemes by their treating physician
according to standard clinical care. Patients were recruited between
August 2016 and October 2018. All patients and/or their legal repre-
sentatives gave written informed consent before entering the study.
The study was approved by the medical ethics committee of the Erasmus
Medical Center, the Netherlands (number MEC 2016-124). The study
was carried out in accordance with the Declaration of Helsinki and the
Regulations on Medical Research with Human Subjects, the Netherlands.
2.2 | Drug concentration measurement
Three blood samples were repeatedly collected for risperidone and
9-hydroxyrisperidone quantification on two separate days. For
patients who initiated risperidone treatment at the start of the study,
blood samples were withdrawn at 12 and 24 weeks follow-up. For
patients who already used risperidone at the start of the study, blood
samples were collected at the start of the study and at 24 weeks
follow-up. Blood samples were collected using venipuncture or the
dried blood spot (DBS) method at random time points, with at least
1 hour between two samples. DBS sampling has experienced renewed
interest in bioanalysis, as it requires only a simple finger prick and less
blood than a venipuncture. DBS is regarded as less painful and stress-
ful for the patient than conventional blood sampling, and can be col-
lected in a home environment, which increases the feasibility of repeated
sampling in children.25 Time of sampling, time of risperidone intake in
the prior 24 hours, risperidone dose and comedication were reported
during sampling. Risperidone and 9-hydroxyrisperidone plasma concen-
trations were measured with previously validated ultrahigh performance
liquid chromatography-mass spectrometry (LC-MS/MS) methods for
plasma and DBS.26–28 The lower limit of quantification (LLOQ) for risper-
idone was 1 μg/L and for 9-hydroxyrisperidone 0.7 μg/L for plasma and
DBS samples. The lower limit of detection (LOD) for plasma risperidone
samples was 0.02 μg/L and for plasma 9-hydroxyrisperidone was
0.22 μg/L; LOD for the DBS risperidone samples was 0.9 μg/L and for
the DBS 9-hydroxyrisperidone samples was 0.5 μg/L.
DBS concentrations were converted to estimated plasma concen-
trations (EPC) using the following formulas with correction for hemat-
ocrit (ht) based on a previously performed clinical validation study28:
EPCrisperidone = DBSconc= 1−htð Þð Þ=1:120
EPC9−hydroxyrisperidone = DBSconc= 1−htð Þð Þ=0:996
In this study hematocrit was standardly measured. When the hemato-
crit value was unknown and could not be extrapolated from a previ-
ous measurement, the median population value was used.
2.3 | Assessment of outcomes
Side effects and effectiveness were prospectively recorded at the
start of the study and at 24 weeks for all patients using and initiating
risperidone treatment.
Patients who initiated risperidone treatment when starting the
study had additional assessments of side effects and effectiveness at
4 and 12 weeks. For patients who already used risperidone at the
start of the study, bodyweight, height, laboratory measurements and
comedication since initiation of risperidone were retrospectively col-
lected from the patient file.
2.3.1 | Side effects
Bodyweight and height were measured at each visit. EPS were
measured with the Abnormal Involuntary Movement Scale
(AIMS),29 filled in by treating physician, nurse or researcher. Seda-
tion was assessed with the Epworth Sleepiness Scale30 and filled in
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by parents. Laboratory indices measured were triglycerides, total
cholesterol, high-density lipoprotein (HDL)-cholesterol, low-density
lipoproteins (LDL)-cholesterol, glucose, hemoglobin A1C (HbA1C) and
prolactin. Laboratory indices were measured at the start of the
study and at 24 weeks follow-up, with an additional measurement
at 12 weeks for patients who had initiated risperidone treatment
at the start of the study.
QT intervals were measured in triplicate from a 12-lead ECG as
described previously31 at the start of the study and after 24 weeks of
follow-up. The QT interval was measured at steady-state heart rates,
using preferably lead II, from the beginning of the onset of the QRS
complex to the end of the T-wave. The measured QT intervals were




RR interval sð Þp
The QT times and RR intervals of the first 10 ECGs were
measured by both a researcher and an experienced paediatric
cardiologist who were blinded for study time point. As these
measurements showed good agreement (<10% difference for all
measurements), the researcher individually performed the remaining
QTc measurements. If there was any doubt, the ECG was also
reviewed by the paediatric cardiologist.
2.3.2 | Effectiveness
The effectiveness of risperidone was assessed by parents and the
treating physician. Parents filled in the Aberrant Behavior Checklist
(ABC),32 a 58-item questionnaire that is sensitive to treatment effects
in children with ASD. The ABC-irritability subscale (ABC-I) was used
as measure for effectiveness; this scale reflects irritability symptoms
with a maximum of 45 points. Treating physicians filled in the Clinical
Global Impression Scale (CGI).29 This scale describes the severity of
psychopathology (CGI-S) and its improvement (CGI-I) by seven cate-
gories, rated by the treating physician. The CGI-S describes the sever-
ity of illness relative to patients with the same diagnosis in ascending
order, with 1 = normal and 7 = extremely ill. The CGI-I rates the
improvement in comparison to the original medication-naive state of
symptoms: 0 = not assessable, 1 = very much better, 2 = much better,
3 = moderately better, 4 = unchanged, 5 = minimally worse, 6 = much
worse.
2.4 | Assessment of covariates
Medication adherence was assessed with questionnaires (Medication
Adherence Rating Scale MARS-5,33 filled in by parents, and a
100-point visual analogue scale (VAS), filled in by parents and treating
physician) and during the last month of follow-up with an electronical
monitoring system (MEMS).34 A VAS score of 100, a MARS score of
25 or a MEMS adherence percentage of 100 represents optimal
adherence on each scale. Comedication was retrieved from medical
records and from pharmacy records. Comedication for ADHD was
recorded for the following drugs which are known to influence
weight: methylphenidate, amphetamine and atomoxetine.
Parents filled in a study questionnaire at every visit, including
questions about the child's diet, physical activity, grapefruit juice
use and over-the-counter self-medication use (including St John's
wort). Diet questions involved whether the child had visited a die-
tician and whether nutritional advice was followed. Physical activity
questions involved the quantification of the child's high-intensity
(sports) and low-intensity (walking or cycling) activity in hours per
week. Familiar cardiometabolic risk was assessed after taking the
family history at the start of the study, as previously defined.35 If
the family history was unknown, it was considered positive for
cardiometabolic risk.
2.4.1 | Laboratory measurements
Renal function (ureum, creatinine), liver function (aspartate amino-
transferase [ASAT], alanine aminotransferase [ALAT], gamma glutamyl
transpeptidase [GGT], alkalic fosfatase [AF], albumin) and haematocrit
were assessed at baseline and during follow-up.
All patients were genotyped for the following cytochrome P450
(CYP) enzymes that could influence pharmacokinetics: CYP3A4,
CYP3A5, CYP2D6 and P-glycoprotein PGP (ABCB1). The following sin-
gle nucleotide polymorphisms were tested: for CYP3A4 *22, for
CYP3A5 *3 and *6, for CYP2D6 *3, *4, *5, *41 and for ABCB1 (PgP)
3435C > T, using genomic DNA yeisolated from EDTA blood, and
analysed using Taqman 50 nuclease DME assays (ThermoFisher Scien-
tific, Carlsbad, CA, USA). All pharmacogenetic testing was performed
in the laboratory of the Erasmus MC, Rotterdam, the Netherlands.
2.5 | Population pharmacokinetic analyses
Population pharmacokinetic analysis was performed by nonlinear
mixed-effects modelling using NONMEM version 7.4.2 (FOCE+I;
ICON Development Solutions, Ellicott City, MD, USA) and PsN Ver-
sion 4.7.0. Pirana software version 2.9.7 was used as an interface
between NONMEM and R (version 3.4.4). Concentrations of
9-hydroxyrisperidone were corrected for molecular weight of
risperidone.
2.5.1 | Base model development
One-, two- and three-compartment models were considered to
describe the concentration-time data based on visual inspection of
the goodness-of-fit plots and a review of the literature. Typical values
for lag-time, first-order absorption rate constant (ka), volume of distri-
bution (V), clearance (CL), and intercompartmental clearance (Q) were
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estimated. As bioavailability (F) could not be quantified, certain param-
eters were estimated as ratios: CL/F, Q/F, and V/F. First, risperidone
data were described and subsequently 9-hydroxyrisperidone data
were added. For each pharmacokinetic parameter interpatient vari-
ability (IPV) was evaluated and shrinkage was calculated for all param-
eters for which IPV was established. A shrinkage value below 25%
was considered acceptable.36 Allometric scaling was used to account
for the influence of bodyweight on pharmacokinetic parameters,
which was explored with a fixed exponent (0.75 for CL and Q, and
1 for V), with exponents estimated by the model. Residual variability
was described with a combined (additive and proportional) error
model, with extra errors for sampling method (DBS versus venipunc-
ture) and concentrations below LLOQ. Concentrations measured
below the LOD were set on half the value of the LOD in combination
with an extra additional error of half the value of the LOD.
Components of the error model estimated to approach zero were
removed. Model selection criteria were a decrease in the NONMEM
objective function value (OFV), goodness-of-fit plots and visual pre-
dictive checks (VPCs). A decrease in the OFV of 3.84 points was con-
sidered statistically significant (P < .05).
2.5.2 | Covariate model development
The following covariates were considered as potential model
covariates: sex, age, dose, dose per kilogram, bodyweight, height,
BMI, CYP3A4 genotype, CYP3A5 genotype, CYP2D6 genotype, P-
glycoprotein (PGP) genotype, comedication, somatic comorbidities,
haematocrit, renal function (ureum, creatinine), liver function
(ASAT, ALAT, GGT, AF), albumin, medication adherence, grapefruit
juice use, St John's wort use and smoking. First, the correlation
between the covariates and IPV was evaluated graphically. Subse-
quently, covariates with a visual relationship with IPV were individ-
ually added to the model. Continuous covariates were described
using an exponential function and categorical covariates using a
proportional function. Covariates that significantly improved the
model with the univariate analysis (P < .05) were selected for
multivariate analysis. The forward inclusion-backward elimination
method was used.37 During the backward elimination process,
covariates that improved the model at a level of P < .001 were
selected. A shark plot was generated for each covariate for case-
deletion diagnostics.
2.5.3 | Internal model evaluation
First, a bootstrap analysis was performed with 1000 simulations.38
The validity of the model was evaluated by comparing the bootstrap
estimates and their 90th percentile range with the values generated
using the original dataset. Second, the model was evaluated with a
VPC stratified by compartment, using a set of 1000 simulated
datasets to compare the observed concentrations with the distribu-
tion of the simulated concentrations.39
2.5.4 | Pharmacokinetic predictions
Model-based individual pharmacokinetic predictions were used as
trough concentration (Ctrough), maximum concentration (Cmax) and
24-hour AUC (AUC24h) were not available for each patient because of
sparse random sampling within the study. These pharmacokinetic
parameters were predicted for risperidone and 9-hydroxyrisperidone
per subject for the days a BMI z-score was known. The Ctrough prior to
the first risperidone administration of the day was used. The Cmax was
calculated for risperidone and was defined as the concentration at
40 minutes after risperidone administration, based on visual
inspection of concentrations simulated by the final model. In case of
multiple dosages per day, the highest Cmax on that day was used for
the analyses.
2.6 | Pharmacodynamic analyses
2.6.1 | Primary outcome
The primary outcome was BMI adjusted for age and weight, the
BMI z-score. A BMI z-score of ≥1 is considered overweight and a BMI
z-score ≥2 is considered obesity according to the World Health Orga-
nization (WHO).40 BMI values were transformed into BMI z-scores
based on the WHO BMI-for age reference values (5-19 years).41
2.6.2 | Secondary outcomes
The following secondary outcomes were analysed: EPS, sedation, tri-
glycerides level, total cholesterol level, HDL-cholesterol level, LDL-
cholesterol level, glucose level, HbA1C level, prolactin level, QTc-time,
CGI-improvement score and ABC-irritability (ABC-I) score. EPS, seda-
tion and CGI-improvement score were considered categorical out-
comes. EPS was defined positive if at least two times mild or one time
moderate was scored with the AIMS. Sedation was defined as an ESS
total score of 1 or higher. Only children for whom a baseline
measurement (before start of risperidone treatment) of the concerning
outcome was available were included in the analyses.
2.7 | Statistical analyses
Generalized and linear mixed-effects models were used to analyse the
longitudinal data. Random effects were employed to capture the het-
erogeneity between the patients. The BMI z-score was considered the
primary outcome. Each pharmacokinetic parameter of risperidone was
separately analysed as predictor versus BMI z-score. Potential relevant
covariates (duration of risperidone use, sex, age, somatic comorbidities,
comedication, IQ, prematurity, physical activity, diet) were tested in each
model and the best model was selected using backwards variable selec-
tion. The final model among all the best models with different
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TABLE 1 Baseline characteristics
Characteristic
Male, n (%) 32 (76.2)
Agea (years) 9.7 (5.3)
Bodyweighta (kg) 32.4 (18.3)
Heighta (m) 1.42 (0.34)
Body mass indexa (kg m−2) 16.18 (4.06)
Body mass index z-scorea −0.32 (1.69)
Ethnicity, n (%)




Triglycerides (mmol/L) 0.57 (0.42)
Total cholesterol (mmol/L) 4.00 (1.00)
HDL-cholesterol (mmol/L) 1.50 (0.49)
LDL-cholesterol (mmol/L) 2.33 (0.79)
Glucose (mmol/L) 4.90 (0.40)
HbA1C (mmol/Mol) 33 (4)
Prolactin (U/L) 0.12 (0.10)
Genotype, n (%)c
CYP2D6
Poor metabolizer 0 (0)
Intermediate metabolizer 27 (64.3)
Normal metabolizer 14 (33.3)
CYP3A4
Poor metabolizer 1 (2.4)
Intermediate metabolizer 6 (14.3)





Poor metabolizer 14 (33.3)
Normal metabolizer 27 (64.3)
Unknown genotype 1 (2.4)
QTc time (ms)a 387 (31)
Clinical global impression scale (CGI-s) scorea 5 (2)
Comorbid psychiatric disorders other than ASD, n (%) 27 (64.3)
Comedication ADHD drugs, n (%)d 10 (23.8)
IQa 100 (40)
Treatment setting, n (%)
Outpatient 37 (88.1)
Inpatient 5 (11.9)
Prior psychotropic treatment, n (%) 25 (59.5)
Physical activitya
High intensity (hours/week) 2.5 (3)
Low intensity (hours/week) 2 (2)
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pharmacokinetic parameters of risperidone was chosen by Akaike infor-
mation criterion.42
The secondary analyses were performed with the pharmacoki-
netic parameter that was selected for the final model of the pri-
mary outcome. This pharmacokinetic parameter was entered as
predictor in univariable models and, if significant, relevant
covariates were added in a stepwise manner. On top of the
covariates for the primary analyses, psychiatric comorbidities, psy-
chotropic treatment before start of risperidone, nonpharmacological
treatment of parent and/or child, and familiar cardiometabolic risk
were checked when relevant.
The correlation between model-based pharmacokinetic parame-
ters was analysed with Pearson's correlation. Changes in BMI z-scores
between baseline and the last visit was assessed with the Wilcoxon
signed-rank test. The explained variance by the final model was calcu-
lated with the conditional pseudo-R2. In all analyses P < .05 was con-
sidered significant and all analyses were performed in R43 (version
3.4.4).
3 | RESULTS
3.1 | Study sample
Forty-two patients were included, of whom 31 initiated risperidone
treatment at the time they were included in the study and
11 already used risperidone before inclusion in the study. The
baseline characteristics of the study sample are presented in
Table 1. The median (interquartile range, IQR) follow-up time since
start of risperidone therapy was 5.7 (4.8) months. The median
(IQR) risperidone daily dose at the end of follow up was 1.0
(0.5) mg and 0.02 (0.02) mg/kg. The majority of children had one
or more comorbid psychiatric disorders besides ASD (64.3%), ie,
attention deficit/hyperactivity disorder (ADHD, 52.4%), oppositional
defiant disorder (11.9%), mood disorder (7.1%), post-traumatic
stress disorder (4.8%) or anxiety disorder (2.4%).
One-hundred and fifty-four DBS samples and 72 plasma samples
were collected. Twenty-one DBS samples (13.6%) were of insufficient
quality for drug quantification, resulting in a total of 205 risperidone
and 205 9-hydroxyrisperidone concentrations. The median (IQR) mea-
sured risperidone concentration was 1.72 (6.19) μg/L in plasma and
3.57 (3.55) μg/L in DBS. The median (IQR) measured
9-hydroxyrisperidone concentration was 7.02 (6.13) μg/L in plasma
and 6.39 (6.72) μg/L in DBS. Haematocrit was known for 85 DBS
measurements in 32 patients, with a median (IQR) haematocrit of 0.40
(0.08) L/L.
The medication adherence was generally high: the median (IQR)
MEMS adherence percentage was 96% (62%), VAS score filled in by
treating physician 100 (4), VAS score filled in by parents 100 (2) and
MARS score filled in by parents 24 (1).
3.2 | Population pharmacokinetic analyses
3.2.1 | Base model
The data was best described using a two-compartment model for
risperidone combined with a one-compartment model for
9-hydroxyrisperidone. IPV on CL of risperidone and CL of
9-hydroxyrisperidone significantly improved the model. The residual
error was described with additional and proportional errors for
risperidone and 9-hydroxyrisperidone, concentrations below the
LOD, concentrations >LOD and <LLOQ, and DBS samples.
Pharmacokinetic parameters are presented in Table 2 and estimates




Increased familiar cardiometabolic risk, n (%)e 18 (42.9)
Formulation of risperidone administration, n (%)
Tablet 31 (73.8)
Oral solution 11 (26.2)
All patients were diagnosed with autism spectrum disorder. The values represent start of risperidone treatment unless otherwise specified. Values repre-
sent total sample of n = 42 patients, except for triglycerides (n = 29), total cholesterol (n = 28), HDL-cholesterol (n = 28), LDL-cholesterol (n = 28), glucose
(n = 30), HbA1C (n = 23), prolactin (U/L), CGI (n = 29), IQ (n = 40), physical activity (n = 11), QTc (n = 25).
Abbreviations: ADHD, attention deficit/hyperactivity disorder; CYP, cytochrome P450; HbA1C, hemoglobin A1C; HDL, high-density lipoprotein; LDL,
low-density lipoproteins; PGP, P-glycoprotein; QTc, corrected QT; aCGI-s, Clinical Global Impression Severity Scale: 1 = normal; 2 = borderline; 3 = mildly
ill; 4 = moderately ill; 5 = markedly ill; 6 = severely ill; 7 = extremely ill.
aPresented as median and interquartile range (IQR) for continuous variables.
bSeven children had one or two parents of non-European descent. Of these, five children had one or two parents with African descent.
cMetabolizing status within the sample was defined as follows: CYP2D6: poor = 2 inactive alleles (eg, *4/*4); intermediate = 1 active and 1 inactive allele
(*1/*3, *1/*4, *1/*5) OR 1 inactive and 1 decreased activity allele (*4/*41); normal = 2 active alleles (*1/*1) OR 1 active and 1 decreased activity allele (eg,
*1/*41); CP3A4: poor = *22/*22, intermediate = *1/*22, normal = *1*1; CYP3A5: expressor = at least 1 active (*1) allele (*1/*3, *1/*6); non-expressor = 2
inactive alleles (*3/*3, *3/*6); ABCB1: poor = 3435TT, normal = 3435CT, 3435CC.
dIncludes methylphenidate, amphetamine, atomoxetine.
eAs defined by American Academy of Pediatrics.35
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3.2.2 | Covariate analysis
No covariates remained significant in multivariate analyses after back-
ward elimination except for bodyweight, which was best described
using fixed exponents with allometric scaling.
3.2.3 | Evaluation of the final model
The bootstrap analysis yielded similar values to the model-based
parameter estimates, except for a larger estimate for the peripheral
V (Vp). The model-based estimate of Vp, however, was within the
bootstrap 90th percentile range, indicating the stability of the model.
The goodness-of-fit-plots showed that the model adequately
described the observed concentrations (Supporting Information
Figure S1). The VPC showed a good predictive performance, although
the lower 90th percentile of the simulated concentrations was slightly
lower than the measured concentrations (Supporting Information
Figure S2).
3.2.4 | Pharmacokinetic predictions
For the time points for which a BMI z-score was known, 270 model-
based individual pharmacokinetic predictions for Ctrough, Cmax and
AUC24h of risperidone and 9-hydroxyrisperidone were calculated. The
correlation between the predicted pharmacokinetic parameters was
moderate to strong (r > 0.5, data not shown), except for risperidone
Ctrough and 9-hydroxyrisperidone AUC24h, which had a weak correla-
tion (r = 0.39).
3.3 | Pharmacodynamic analyses
3.3.1 | Primary outcome: BMI z-scores
Two hundred and seventy BMI z-scores were available in
42 patients; for three patients no baseline BMI z-score was
available. The mean BMI z-score increased significantly during
follow-up from −0.28 ± 1.34 at baseline to 0.26 ± 1.24 at end of
follow-up (P < .001).
A higher risperidone and 9-hydroxyrisperidone exposure signifi-
cantly predicted higher BMI z-scores during follow up for all pharma-
cokinetic parameters (Ctrough, Cmax and AUC24h P < .001). Significant
covariates in multivariate analyses were risperidone duration of use
(months) and comedication for ADHD (P < .05).
The sum Ctrough most strongly predicted BMI z-scores during
follow-up, together with the significant covariates: sum Ctrough
(β = 0.042, P < .001), duration of use (β = −0.009, P < .001) and ADHD
comedication (β = −0.340, P = .004) with an intercept of −0.040
(P = .836). The relationship between sum Ctrough and BMI z-scores is
shown in Figure 1 and Table 3.
The explained variance in BMI z-scores of the final model with
sum Ctrough was 90.4%, which was higher than with risperidone dose
at time of measurement (89.3%).
3.3.2 | Secondary outcomes
Sum Ctrough significantly predicted sedation, prolactin levels and ABC-
irritability score with correction for relevant covariates. No association
was found between sum Ctrough and EPS, triglycerides, total choles-
terol, HDL cholesterol, LDL cholesterol, glucose, HBA1C, prolactin or
QTc time and response based on CGI-improvement score. The results
of the effectiveness analyses are presented in Table 3 and the results
of the secondary side-effects analyses are presented in Supporting
InformationTable S2.
3.3.3 | Therapeutic window
Based on the estimated coefficients for BMI z-scores, ABC-I score
and the relevant covariates, a plausible therapeutic window for a child
10 years of age, with 3 months of risperidone treatment and without
ADHD comedication is visualized in Figure 2. Assuming a BMI z-score
<1 and an ABC-I score <11 as relevant cut-offs for treatment success
with acceptable weight gain, the theoretical therapeutic window of
the sum Ctrough would be between 15 and 25 μg/L.
4 | DISCUSSION
This study demonstrates that higher risperidone and
9-hydroxyrisperidone plasma concentrations are associated with
more weight gain, more sedation, higher prolactin levels and





tlag (h) 0.42 0.42 (0.40-0.50)
Ka (L/h) 18.6 34.2 (4.0-2587.1)
Vc/F
a (L/70 kg) 107 107.2 (85.5-142.1)
Vp/F
a (L/70 kg) 46.2 426.3 (39.1-9671.2)
Q/Fa (L/h/70 kg) 3.31 4.4 (1.6-14.7)
CL/Fa (L/h/70 kg) 23.9 24.2 (19.5-32.1)
IPV CL 80% (6%) 82% (66-103)
VCM/F
a (L/70 kg) 111 101.4 (75.2-181.9)
CLM/F
a (L/h/70 kg) 5.19 5.2 (4.6-5.7)
IPV CLM 28% (12%) 25% (17-34)
St Johns wort and grapefruit juice were not tested as covariates, as no
children used these during follow-up.
Abbreviations: tlag, lag time; Ka, absorption rate constant; V, volume of dis-
tribution; CL, clearance; IPV, interpatient variability; M, metabolite,
9-hydroxyrisperidone; P, peripheral; C, central; RSE, relative standard
error.
aAllometric scaling with exponent 1 for V, and 0.75 for CL and Q.
b90th percentile based on bootstrap with n = 279 successful runs.
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increased effectiveness in children and adolescents with ASD and
behavioural problems. The sum trough concentration of risperidone
and 9-hydroxyrisperidone was the most predictive pharmacokinetic
parameter.
The risperidone and 9-hydroxyrisperidone population pharmaco-
kinetic parameters found in this study are comparable to previously
described values in children and adolescents.44,45 After adjusting for
bodyweight, these pharmacokinetic parameters are similar to adults.45
The effects of demographic and biochemical characteristics on risperi-
done plasma concentrations in youths have not been studied exten-
sively. While several studies did not find an influence of sex,44–46
some found higher total plasma concentrations in girls than boys47
F IGURE 1 Sum trough concentration versus
BMI z-scores. BMI, body mass index; sum,
risperidone and 9-hydroxyrisperidone
TABLE 3 Association between trough concentrations of risperidone + 9-hydroxyrisperidone, BMI z-score and secondary effectiveness
outcomes
Variable n (obs) Estimate Standard error P value
Primary outcome
BMI z-score 42 (270)
Sum Ctrough 0.042 0.005 <.001
Duration of use −0.009 0.002 <.001
Comedication ADHD −0.340 0.116 .004
Secondary outcomes: effectiveness
CGI – response 29 (107)
Sum Ctrough 0.300 0.158 .057
Duration of use 0.445 0.183 .015
ABC – Irritability 42 (121)
Sum Ctrough −0.281 0.093 .003
Age at start −1.390 0.398 .001
The median (IQR) predicted sum Ctrough was 10.07 (11.54) μg/L. The influence of diet and physical activity could not be analysed due to too many
missing values.
Abbreviations: ABC-I, Aberrant Behavior Checklist – irritability score; BMI, body mass index; CGI, Clinical Global Impression Scale; obs, number of
observations.
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and others the opposite.48 Within our sample, no influence of sex was
found, but our sample mainly consisted of boys. The activity of the
CYP2D6 enzyme has repeatedly been shown to strongly affect risperi-
done clearance in children and adolescents,44,45,49 but was not found
as significant covariate due to the absence of poor and extensive
metabolizers in our study population. The influence of polymorphisms
in other cytochrome P450 enzymes CYP3A4, CYP3A5 and the trans-
port protein PGP on risperidone concentrations has not been previ-
ously studied in children and adolescents, despite evidence for this
influence in adults.50,51 Our study is the first to examine these poly-
morphisms for risperidone in youths, but did not find any significant
effect of polymorphisms in these genes on risperidone
pharmacokinetics.
Higher risperidone and 9-hydroxyrisperidone concentrations
predicted higher BMI z-scores during risperidone treatment in children
and adolescents. The sum trough concentration of risperidone and
9-hydroxyrisperidone, also referred to as the “active moiety”, was
found to be the most predictive pharmacokinetic parameter. This con-
firms the recommendation in current therapeutic drug monitoring
guidelines,52 but was not self-evident, as for other drugs, including
antibiotic drugs, it is known that maximum concentrations or AUCs
can predict outcomes better than trough concentrations.53 Two other
studies have investigated the relationship between both risperidone
and 9-hydroxyrisperidone concentrations and BMI z-scores in children
and adolescents. One of these two studies did find higher risperidone
metabolite and sum concentrations in children and adolescents with
higher BMI z-scores,48 the other did not find any association.54 How-
ever, both studies had a cross-sectional design without baseline mea-
surement, and were not able to take weight gain into account. In
adults, to date no studies have investigated the relationship between
risperidone plasma concentrations and weight gain.55
The analysis of the relationship between risperidone plasma con-
centrations and weight gain is complicated, as this relationship is bidi-
rectional. Risperidone exposure may influence bodyweight in a
pharmacodynamic way, but bodyweight also moderates risperidone
exposure by pharmacokinetic processes. Higher body weight is
expected to result in lower risperidone concentrations with an
unaltered dose, as volume of distribution and clearance increase with
bodyweight as a result of allometric scaling. Therefore, the pharmaco-
dynamic explanation of the relationship is favoured, as in our study
higher concentrations were found with higher bodyweights. Still, it is
unknown how well the established allometric scaling exponents fit
paediatric populations with overweight.56 For risperidone, a relatively
lipophilic drug, the volume of distribution is likely to increase with
increasing fat mass, but for 9-hydroxyrisperidone, the more hydro-
philic metabolite, this is more unlikely. Further research is needed to
clarify the relationship between measured risperidone concentrations,
rather than predicted concentrations, and overweight in paediatric
patients.
Higher risperidone sum trough concentrations were also related
to more sedation, prolactin elevation and effectiveness in our sample.
In adults, the risperidone exposure-response relationship has been
studied almost exclusively in schizophrenia patients, yielding con-
flicting results. While some studies found a higher risperidone plasma
concentrations predicting better response, others found the oppo-
site.55 The positive correlation with extrapyramidal symptoms is bet-
ter established, although different plasma thresholds are reported,
including >40 μg/L,57 >180 μg/L58 or > 74 μg/L.55 As a result, a thera-
peutic reference range of risperidone in adults has not yet been
clearly established, but is proposed as 20-60 μg/L for schizophrenia
by the AGNP consensus guideline.52
For children and adolescents, no therapeutic reference range is
known, although it is suggested that optimal risperidone concentra-
tions in children with impulsive-aggressive symptoms are lower than
in adults with schizophrenia.22 Our findings confirm this, and show
that optimal concentrations might depend on the child's age at start
of risperidone therapy, duration of treatment and comedication with
ADHD drugs. When accounting for these variables, a therapeutic win-
dow of risperidone in children and adolescents with autism and
behavioural problems seems to exist. For example, for a child 10 years
old, after 3 months of risperidone treatment without ADHD
comedication, the theoretical therapeutic range would be 15-25 μg/L,
when a BMI z-score <1 and ABC irritability score <11 are considered
as optimal treatment outcomes. This response corresponds to a 25%
reduction in ABC irritability score, which has been previously defined
as clinically relevant.59
Although this study demonstrates a rationale to explore the
added value of therapeutic drug monitoring in this population, more
research is needed to better define the therapeutic reference range of
risperidone in these youths. Future studies should assess measured
rather than predicted sum trough concentrations and focus on their
predictive value in an early treatment phase for weight gain during
later follow-up. Eventually, a randomized controlled trial should evalu-
ate the added value of risperidone titration towards optimal concen-
trations versus treatment as usual. These efforts should be made
before therapeutic drug monitoring of risperidone in youths can be
routinely used as standard care.
F IGURE 2 Example of theoretical therapeutic window. The
relationship between BMI z-scores, ABC-I scores and sum Ctrough for a
child 10 years old, with 3 months of risperidone treatment and
without ADHD comedication. The grey lines indicate a theoretical
therapeutic window (15-25 μg/L) for a BMI z-score <1 and a ABC-I
score <11. BMI, body mass index; ABC-I, Aberrant Behavior Checklist
– Irritability scale; sum Ctrough, sum of trough concentrations of
risperidone and 9-hydroxyrisperidone
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The findings of this study should be interpreted in the light of its
limitations. First, the study had a sparse sampling design with differ-
ent sampling methods, including venous sampling and dried blood
spot sampling. This design was chosen to minimalize the patient bur-
den and increase the study feasibility, as has been previously advised
for paediatric pharmacokinetic trials.25 This, however, resulted in a
higher variability in measured and predicted pharmacokinetic concen-
trations, further enhanced by the relatively large share of the mea-
sured risperidone concentrations below the LOD. We have reduced
these variabilities in the analyses with the development of an exten-
sive pharmacokinetic residual error model, although this resulted in
less accuracy in the estimation of Vp/F. Second, the analysis of the
relationship between risperidone exposure and effects was done with
model-based concentrations rather than the measured concentra-
tions themselves. Although this is suboptimal compared to really
measured exposure, the model-based concentrations showed a good
fit with measured concentrations. Moreover, this allowed for an anal-
ysis of not only trough concentrations, but also peak concentrations
and AUC24h. Third, due to a limited sample size, relatively few
patients had high risperidone sum trough concentrations. These
patients had a quite large impact on the regression analyses. How-
ever, the mg/kg doses and characteristics of these patients were
within the range of the total sample, thus reflecting average patients.
Fourth, the sample size was not powered for the secondary out-
comes, thus possibly leading to nonsignificant results. Fifth, this study
has the typical limitations of naturalistic study designs in analysing
the exposure-response relationship,60 as placebo-responders and
patients with side effects are likely to receive lower dosages, while
nonresponders are likely to receive higher dosages. This might have
led to an over- or underestimation of the exposure-response rela-
tionship. Lastly, although a large panel of pharmacogenetic polymor-
phisms was tested for its pharmacokinetic influence, candidate genes
that might be relevant for pharmacodynamic outcomes were cur-
rently not tested; these, however, are of interest for future
research.61
This is the first study that prospectively investigated the relation-
ship between risperidone pharmacokinetic parameters, side effects
and effectiveness in children and adolescents with autism spectrum
disorder and severe behavioural problems. The finding that the risperi-
done sum trough concentration predicts weight gain, other side
effects and response indicates that therapeutic drug monitoring might
improve the safety and efficacy of risperidone treatment in this vul-
nerable population.
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